secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001558370-23-009260
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virios Therapeutics reports Q1 2023 net loss of $1.5M; FDA amenable to IMC-1 Phase 3 proposal
--------------------------------------------------------------------------------

- Net loss $1.5M ($0.08 per share) vs $4.0M ($0.48) in Q1 2022; R&D expenses fell to $0.5M from $2.8M.
- Cash $5.3M as of March 31, 2023; company expects runway into Q2 2024, but IMC-1 trials need additional funding.
- FDA amenable to Phase 3 program for IMC-1 (famciclovir/celecoxib) for fibromyalgia, pending review of chronic toxicology reports submitted in May 2023.
- Top-line results from exploratory Long-COVID study (valacyclovir/celecoxib) expected in June 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000155837023009260/0001558370-23-009260-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000155837023009260/tmb-20230511x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-009260

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer